title: How to Overcome Scientific Standstill for Very Rare Diseases: Clinical Trials or Clinical Registries?
authors.forename: D
authors.initials: D
authors.lastname: Körholz
authors.forename: D
authors.initials: D
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: von Kries
authors.forename: C
authors.initials: C
authors.lastname: Mauz-Körholz
authors.forename: U
authors.initials: U
authors.lastname: Göbel
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends*; D002648:Child; D006301:Health Services Needs and Demand / Q000639:trends; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010372:Pediatrics / Q000639:trends*; D016032:Randomized Controlled Trials as Topic; D035583:Rare Diseases / Q000188:drug therapy*; D012042:Registries; D020379:Risk Adjustment
chemical_list: D000970:Antineoplastic Agents